Results 191 to 200 of about 106,748 (296)

CAR‐HEMATOTOX score to predict risk of poor outcomes with odronextamab in heavily pretreated B‐cell non‐Hodgkin lymphoma

British Journal of Haematology, EarlyView.
High versus low baseline CAR‐HEMATOTOX scores were associated with poorer safety and efficacy outcomes in patients with R/R B‐NHL who received odronextamab in the ELM‐1 and ELM‐2 studies. The CAR‐HEMATOTOX score may provide a readily available measure for identifying patients at risk of inferior clinical outcomes with odronextamab treatment.
Matthew Matasar, David Tucker, Tae Min Kim, Yuan Cheng, Jingjin Li, Saleem Shariff, Hesham Mohamed, Manjusha Namuduri, Aafia Chaudhry, Stefano Luminari   +9 more
wiley   +1 more source

Breast implant-associated diffuse large cell B-cell lymphoma (BIA-DLBCL) - a case report and a treatment algorithm. [PDF]

JPRAS Open
Borgolte MB, Sokolow AJ, Bittner MA, Schreml S, Klapper W, von Fritschen U, Schiltz D.   +6 more
europepmc   +1 more source

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source

Peripheral targets for neuropathic pain

British Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour, Cosmin I. Ciotu, Felix J. Resch, Michael J. M. Fischer   +3 more
wiley   +1 more source

Spatial and maturational characterisation of tertiary lymphoid structures predicts immunotherapy response in extensive-stage small cell lung cancer. [PDF]

Clin Transl Immunology
Wang H, Shang X, Jiang Y, Zhao C, Li Z, Zhang C, Xu Q, Du S, Lin J, Wang H.   +9 more
europepmc   +1 more source

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

British Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli, Cristina Madaudo, Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna   +4 more
wiley   +1 more source

Dural Follicular Non-Hodgkin Lymphoma Mimicking a Chronic Subdural Hematoma: A Case Report and Literature Review. [PDF]

Cureus
Arellanes-Chavez CA, Ramos Mertinez E.
europepmc   +1 more source

Multi‐Omics Integration Reveals Metabolic Reprogramming and EMT‐Driven Metastasis in Triple‐Negative Breast Cancer

Cancer Science, EarlyView.
Integrated transcriptomic, metabolomic, and spatial proteomic profiling of TNBC tumors identifies a metastatic‐associated molecular landscape characterized by EMT activation, metabolic reprogramming, and tumor microenvironment (TME) remodeling. Multi‐omics integration reveals coordinated alterations in EMT signatures, amino acid metabolism, immune ...
Yuheng Pang, Yuefeng Shang, Wenjing Wang, Tong Liu, Xiaolong Zou   +4 more
wiley   +1 more source

Evolution of CAR‐T Therapy: Functional Engineering, Manufacturing Innovation, and Future In Vivo Strategies

Cancer Science, EarlyView.
CAR‐T therapy is evolving across four interconnected dimensions: functional engineering, manufacturing innovation, alternative cell sources, and in vivo CAR programming. Together, these advances address limitations in therapeutic efficacy, safety, manufacturing complexity, scalability, and accessibility, providing complementary paths toward the next ...
Yukimi Sakoda
wiley   +1 more source